Optimization of transfection methods for human lymphoblast TK6 cell line
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index; none of the 62 sources its claims cite is checked for support yet.
Abstract
Transfection has recently gained attention in the field of biomedical research due to its ability to manipulate gene expression. Every mammalian cell type has a characteristic set of requirements for optimal transfection. Some cells can be difficult to transfect and require optimization for successful transfection. Human lymphoblast TK6 cell line, an important cell line for genotoxic studies, is known to be extremely hard to transfect. Thus, optimizing transfection methods for human lymphoblast TK6 are increasingly important. To accomplish this, TK6 human lymphoblasts were transfected with plasmid constructs that expressed green fluorescent protein (GFP) and NanoLuc® activity. We compared the transfection efficiency of three commercially available transfection reagents, including Amaxa 96-well Nucleofection procedure using various solutions (SF, SE, and SG), Lipofectamine LTX, and Metafectene Pro®. The transfection efficiency and toxicity of various reagents were tested by fluorescence microscopy, luciferase activity, and cell viability assays. Amaxa 96-well Nucleofection Solution SF was identified as the best transfection reagent due to its relatively high luciferase activity, acceptable cell viability (80%), and GFP transfection efficiency (80%). Optimal conditions for transfection utilized with this reagent included 0.4 μg of plasmid DNA, 1.8 × 105 cells, and using the DS 137 Nucleofector program.
Overview
CoChat Summary
TL;DR
This study compared Metafectene Pro, Lipofectamine LTX, and Amaxa 96-well Nucleofection for transfecting hard-to-transfect human TK6 lymphoblasts. Amaxa Nucleofection with Solution SF and program DS 137 was identified as optimal, yielding high GFP transfection efficiency, acceptable viability, and the strongest luciferase signal among the tested reagents.
Key findings
- Amaxa 96-well Nucleofection Solution SF with program DS 137 was best: the abstract reports optimized conditions of 0.4 µg plasmid DNA, 1.8 × 10^5 cells, 80% viability, and 80% GFP transfection efficiency; results report ~80% GFP efficiency and ~85% viability for 0.4 µg, with luciferase RLU ~5.4 × 10^5 (discussion reports RLU = 5.1 × 10^5 and toxicity ~15%). Amaxa yielded the strongest luciferase signal of the three reagents after 24 and 36 h.
- Metafectene Pro gave ~96% cell viability regardless of ratio, with maximal transfection efficiency at reagent:DNA ratio 3 using 1.0 µg DNA at 24 and 36 h, but no nanoluciferase activity was detected under optimal conditions, so it could not be used in this system.
- Lipofectamine LTX achieved at least 80% transfection efficiency with no significant toxicity at 24 and 36 h; luciferase activity was significantly greater than control, with a 30% increase at 36 h versus 24 h, and nanoluciferase expression around 1.8 × 10^5 RLU.
- In secondary Amaxa optimization, 0.4 µg DNA gave significantly greater viability than 0.5 µg at 24 and 36 h, with no significant difference in GFP efficiency between 0.4 and 0.5 µg; 0.4 µg pNL1.1CMV produced significantly greater luciferase activity than 0.5 µg, with maximal expression at 36 h.
Methods
- TK6 human p53-proficient B-lymphoblastic cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine and 10% FBS at 37°C/5% CO2; cells were passaged at 2.0 × 10^5 cells/ml, media changed every 36 h, and passaged 12–14 h before experiments.
- Plasmids used were pGFPmax (GFP), pNL1.1.CMV (nanoluciferase), and pNL1.2[Nluc] promoter-less control. Transfections used Metafectene Pro (ratios 1:2–1:6; 0.5/1.0 µg DNA), Lipofectamine LTX (0.5–1.0 µg DNA; PLUS 1.5–2.5 µl; lipofectamine 3.75–10.0 µl), and Amaxa 96-well Nucleofection (initial SE/SF/SG with 0.4 µg pmaxGFP; secondary SF with DS 137 and 0.4/0.5 µg pGFPmax or pNL1.1CMV).
- Assays at 24 and 36 h included GFP fluorescence microscopy for transfection efficiency (GFP+ cells divided by total cells by brightfield), Nano-Glo luciferase assay, and Vi-cell viability. Transfection experiments were conducted in duplicates and repeated twice; luciferase assays are reported as triplicates/duplicates.
Limitations
- The paper has no dedicated limitations section. Stated caveats include: Amaxa nucleofection was more toxic than the other methods due to long-lasting pulses or polarization from the electric field and gave overall weak but acceptable viability; Metafectene Pro produced no detectable nanoluciferase activity, possibly due to inhibition/interference with NanoLuc; and no single delivery method or reagent works for all cells, with cytotoxicity and efficiency varying by reagent, protocol, and cell type.
- Evident from the text: only one cell line (TK6) was tested; experiments were in duplicates and repeated twice; statistical tests are not named; some optimization/viability data are “not shown”; and reported values vary between abstract, results, and discussion (e.g., viability 80% vs ~85%; RLU ~5.4 × 10^5 vs 5.1 × 10^5).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
0 Valid · 0 Not valid · 19 Not checked · 52 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No signi cant (p>0.05)differences in cell viability between control cells that received no DNA and cells that were transfected with various reagent/DNA ratios for both 24 and 36h post transfection (Fig 1A).”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Transfection e ciency of cells that received pGFPmax was signi cantly (p<0.05)greater than the control cells that received no DNA (Fig. 1B).”
- Also stated in: § Optimizing transfection conditions for Metafectene Pro transfection reagent · plain
“Transfection e ciency of cells that received the pGFPmax plasmid was signi cantly (p<0.05)greater than control cells that received no DNA (Fig. 2B).”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Optimizing transfection conditions for Metafectene Pro transfection reagent · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maximal transfection e ciency was achieved at reagent to DNA ratios of 3 for both 24 and 36h post transfection (Fig. 1B).”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Figure 1A cell viability (~96%) in this cell line using Metafectene® Pro was comparable regardless of the ratio (Fig 1A).”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, the results of Fig. 1 demonstrate that optimal transfection conditions for the Metafectene Pro transfection reagent occur at reagent/DNA ratio of 3 when 1.0ug of DNA is utilized for transfection.”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 71 claims and every source verdict.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Abstract
“E cient conditions for transfection utilized with this reagent included 0.4µg of plasmid DNA, 1.8 x 10 5 cells, and the DS 137 nucleofector program.”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Secondary nucleofection optimization
“The cells were re-suspended to a density of 1.0 x 10 6 cells/20ul in the supplemented nucleofection solution SF (Lonza).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Lipofectamine transfection
“TK6 cells were seeded in 6-well plates at a density of 1.0 x 10 5 and 1.0 x 10 6 cells/well.”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Lipofectamine LTX
“cells were seeded in 6-well plates at 0.5 x 10 5 and 1.0 x 10 6 cells/well”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Secondary optimization of nucleofection conditions by using the Amaxa nucleofector
“Luciferase activity was RLU ~5.4 X10 5 , as opposed to 1.8X10 5 RLU obtained for lipofectamine LTX.”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Discussion
“In this study transfecting TK6 with 0.4µg of plasmid DNA using reagent SF, program DS 137 as was associated with high transfection e ciency (~ 80%) and luciferase activity (RLU = 5.1 X 10 5 ) with acceptable cell toxicity (~ 15%).”
Citations
Cites
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Dalby, B. (2004) · Methods · doi:10.1016/j.ymeth.2003.11.023 · Cited by 619
Nanomedicine : nanotechnology, biology and medicine.
ScienceDirect (2005) · Cited by 586
Physical methods for gene transfer: Improving the kinetics of gene delivery into cells
MEHIERHUMBERT, S., & GUY, R. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.007 · Cited by 395
DNA Nanoparticles and Development of DNA Delivery Vehicles for Gene Therapy
Vijayanathan, V., Thomas, T., & Thomas, T. J. (2002) · Biochemistry · doi:10.1021/bi0203987 · Cited by 360
Satkauskas, S., Bureau, M. F., Puc, M., Mahfoudi, A., Scherman, D., Miklavcic, D., & Mir, L. M. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0526 · Cited by 306
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes
Ganesh, L., Burstein, E., Guha-Niyogi, A., Louder, M. K., Mascola, J. R., Klomp, L. W. J., Wijmenga, C., Duckett, C. S., & Nabel, G. J. (2003) · Nature · doi:10.1038/nature02171 · Cited by 226
Transfection Techniques for Neuronal Cells: Table 1.
Karra, D., & Dahm, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0183-10.2010 · Cited by 209
An Efficient Low Cost Method for Gene Transfer to T Lymphocytes
Chicaybam, L., Sodre, A. L., Curzio, B. A., & Bonamino, M. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060298 · Cited by 129
Hu, B., Zou, Y., Zhang, L., Tang, J., Niedermann, G., Firat, E., Huang, X., & Zhu, X. (2019) · Human Gene Therapy · doi:10.1089/hum.2017.234 · Cited by 124
Gene Transfer Approaches to the Healing of Bone and Cartilage
Lieberman, J. R., Ghivizzani, S. C., & Evans, C. H. (2002) · Molecular Therapy · doi:10.1006/mthe.2000.0663 · Cited by 111
Hunt, M. A., Currie, M. J., Robinson, B. A., & Dachs, G. U. (2010) · PubMed Central · Cited by 96
O'MAHONEY, J. V., & ADAMS, T. E. (1994) · DNA and Cell Biology · doi:10.1089/dna.1994.13.1227 · Cited by 93
An improved method for increasing the efficiency of gene transfection and transduction.
Shi, B., Xue, M., Wang, Y., Wang, Y., Li, D., Zhao, X., & Li, X. (2018) · Europe PMC (PubMed Central) · Cited by 92
Hughes, M. M., Hooftman, A., Angiari, S., Tummala, P., Zaslona, Z., Runtsch, M. C., McGettrick, A. F., Sutton, C. E., Diskin, C., Rooke, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.072 · Cited by 90
Nakayama, A., Sato, M., Shinohara, M., Matsubara, S., Yokomine, T., Akasaka, E., YOSHIDA, M., & Takao, S. (2007) · Cloning and Stem Cells · doi:10.1089/clo.2007.0021 · Cited by 75
Lenz, P., Bacot, S. M., Frazier-Jessen, M. R., & Feldman, G. M. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00169-8 · Cited by 72
Non-Viral Gene Delivery with Cationic Liposome–DNA Complexes
Ewert, K. K., Ahmad, A. K., Bouxsein, N. F., Evans, H. M., & Safinya, C. R. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-237-3_10 · Cited by 69
HIGD2A is Required for Assembly of the COX3 Module of Human Mitochondrial Complex IV
Hock, D. H., Reljić, B., Ang, C., Muellner-Wong, L., Mountford, H. S., Compton, A. G., Ryan, M. T., Thorburn, D. R., & Stroud, D. A. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002076 · Cited by 66
Novel non-viral method for transfection of primary leukemia cells and cell lines
Schakowski, F., Buttgereit, P., Mazur, M., Märten, A., Schöttker, B., Gorschlüter, M., & Schmidt-Wolf, I. G. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-1 · Cited by 61
Yoshinaga, N., Uchida, S., Naito, M., Osada, K., Cabral, H., & Kataoka, K. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.01.023 · Cited by 59
Effective gene delivery to adult neurons by a modified form of electroporation
Leclere, P. G., Panjwani, A., Docherty, R., Berry, M., Pizzey, J., & Tonge, D. A. (2005) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.08.012 · Cited by 58
Avci‐Adali, M., Behring, A., Keller, T., Krajewski, S., Schlensak, C., & Wendel, H. P. (2014) · Journal of Biological Engineering · doi:10.1186/1754-1611-8-8 · Cited by 55
Rapid and efficient electroporation-based gene transfer into primary dissociated neurons
Dityatev, A. E., Hammond, M. S. L., Thiel, C., Ruonala, M. O., Delling, M., Siebenkotten, G., Nix, M., & Dityatev, A. E. (2003) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(03)00202-4 · Cited by 55
Song, H.-Y., Chien, C., Yarmishyn, A. A., Chou, S., Yang, Y., Wang, M., Wang, C., Leu, H., Yu, W.-C., Chang, Y., et al. (2019) · Cells · doi:10.3390/cells8040327 · Cited by 50
DEAE-Dextran Transfection of Mammalian Cultured Cells
Schenborn, E. T., & Goiffon, V. (2003) · Humana Press eBooks · doi:10.1385/1-59259-686-x:147 · Cited by 48
Herrero, A. B., Quwaider, D., Corchete, L. A., Mateos, M., García‐Sánz, R., & Gutierrez, N. C. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15078 · Cited by 47
A Method to Evaluate the Efficiency of Transfection Reagents in an Adherent Zebrafish Cell Line
Sandbichler, A. M., Aschberger, T., & Pelster, B. (2012) · BioResearch open access · doi:10.1089/biores.2012.0287 · Cited by 46
Kim, Y., Ahmed, S., Baki, M. A. A., Kumar, S., Kim, K. W., Park, Y., & STANLEY, D. W. (2020) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2020.103743 · Cited by 40
Estimating transfection efficiency in differentiated and undifferentiated neural cells
Alabdullah, A. A., Al-Abdulaziz, B., Alsalem, H., Magrashi, A. I., Pulicat, S. M., Almzroua, A., Almohanna, F., Assiri, A. M., Tassan, N. A. A., & Al-Mubarak, B. R. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4249-5 · Cited by 40
Genetic transformation of the dinoflagellate chloroplast
Nimmo, I. C., Barbrook, A. C., Lassadi, I., Chen, J. E., Geisler, K., Smith, A. G., Aranda, M., Purton, S., Waller, R. F., Nisbet, R. E. R., et al. (2019) · eLife · doi:10.7554/elife.45292 · Cited by 39
Schiøtz, B. L., Rosado, E. G., Bækkevold, E. S., Lukacs, M. F., Mjaaland, S., Sindre, H., Grimholt, U., & Gjøen, T. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-136 · Cited by 38
Non-Viral Vector Mediated Gene Delivery: the Outsider to Watch Out For in Gene Therapy
Nyamay’Antu, A., Dumont, M., Kedinger, V., & Erbacher, P. (2019) · Cell and Gene Therapy Insights · doi:10.18609/cgti.2019.007 · Cited by 36
Cheung, W. Y., Hovey, O. F. J., Gobin, J., Muradia, G., Mehic, J., Westwood, C., & Lavoie, J. R. (2018) · Stem Cells International · doi:10.1155/2018/1310904 · Cited by 34
Park, J.-S., Surendran, S., Kamendulis, L. M., & Morral, N. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-8 · Cited by 34
Enhancement and optimization of plasmid expression in femtosecond optical transfection
Praveen, B. B., Stevenson, D. J., Antkowiak, M. K., Dholakia, K., & Gunn, F. J. (2011) · Journal of Biophotonics · doi:10.1002/jbio.201000105 · Cited by 34
Design of transfections: Implementation of design of experiments for cell transfection fine tuning
Mancinelli, S., Turcato, A., Kisslinger, A., Bongiovanni, A., Zazzu, V., Lanati, A., & Liguori, G. L. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27918 · Cited by 33
Nonviral gene delivery to T cells with Lipofectamine LTX
Harris, E., Zimmerman, D., Warga, E., Bamezai, A. K., & Elmer, J. J. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27686 · Cited by 32
Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa and Biosimilars
Riccetti, L., Sperduti, S., Lazzaretti, C., Klett, D., Pascali, F. D., Paradiso, E., Limoncella, S., Potì, F., Tagliavini, S., Trenti, T., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00503 · Cited by 32
Mollah, M. M. I., & Kim, Y. (2021) · Archives of Insect Biochemistry and Physiology · doi:10.1002/arch.21795 · Cited by 32
Effective gene suppression using small interfering RNA in hard-to-transfect human T cells
Yin, J., Ma, Z., Selliah, N., Shivers, D. K., Cron, R. Q., & Finkel, T. H. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.01.023 · Cited by 31
Marrone, L., Bus, C., Schöndorf, D. C., Fitzgerald, J. C., Kübler, M., Schmid, B., Reinhardt, P., Reinhardt, L., Deleidi, M., Levin, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192497 · Cited by 31
Efficient and gentle siRNA delivery by magnetofection
Ensenauer, R. E., Hartl, D., Vockley, J., Roscher, A. A., & Fuchs, U. (2010) · Biotechnic & Histochemistry · doi:10.3109/10520291003675485 · Cited by 31
Nematollahi, M. H., Torkzadeh-Mahanai, M., Pardakhty, A., Ebrahimi, H. A., & Asadikaram, G. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1392316 · Cited by 30
Thumann, G., Stöcker, M., Maltusch, C., Salz, A. K., Barth, S., Walter, P., & Johnen, S. (2009) · Gene Therapy · doi:10.1038/gt.2009.124 · Cited by 29
Interferences with Luciferase Reporter Enzymes
Auld, D. S., & Inglese, J. (2016) · Cited by 29
Kim, D., Park, J., Leem, Y., Park, J.-E., & Kim, H.-S. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09943-6 · Cited by 28
Orth, P., Weimer, A., Kaul, G., Kohn, D., Cucchiarini, M., & Madry, H. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0071-8 · Cited by 28
Size Specific Transfection to Mammalian Cells by Micropillar Array Electroporation
Zu, Y., Huang, S., Lü, Y., Liu, X., & Wang, S. (2016) · Scientific Reports · doi:10.1038/srep38661 · Cited by 27
Efficient transfection of primary zebrafish fibroblasts by nucleofection
Badakov, R., & Jaźwińska, A. (2006) · Cytotechnology · doi:10.1007/s10616-006-9018-3 · Cited by 27
Magnetofection is superior to other chemical transfection methods in a microglial cell line
Smolders, S., Kessels, S., Smolders, S., Poulhès, F., Zelphati, O., Sapet, C., & Brône, B. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.09.017 · Cited by 26
Cell type differences in activity of the Streptomyces bacteriophage C31 integrase
Maucksch, C., Aneja, M. K., Hennen, E., Bohla, A., Hoffmann, F., Elfinger, M., Rosenecker, J., & Rudolph, C. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn532 · Cited by 26
Impact of the interplay between stemness features, p53 and pol iota on replication pathway choices
Ihle, M., Biber, S., Schroeder, I. S., Blattner, C., Deniz, M., Damia, G. L. M., Gottifredi, V., & Wiesmüller, L. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab526 · Cited by 25
Kataoka, H., Saeki, A., Hasebe, A., Shibata, K., & Into, T. (2020) · Food Science & Nutrition · doi:10.1002/fsn3.2063 · Cited by 20
DNA–METAFECTENE™ PRO complexation: a physical chemistry study
Alatorre‐Meda, M., González‐Pérez, A., & Rodríguez, J. R. (2010) · Physical Chemistry Chemical Physics · doi:10.1039/b920900j · Cited by 19
Hasan, M. M., Ragnarsson, L. K. N., Cardoso, F. C., & Lewis, R. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0243645 · Cited by 18
Intronic tRNAs of mitochondrial origin regulate constitutive and alternative splicing
Hoser, S. M., Hoffmann, A., Meindl, A., Gamper, M., Fallmann, J., Bernhart, S. H., Müller, L., Ploner, M., Misslinger, M., Kremser, L., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02199-6 · Cited by 16
Cerda, M. B., Batalla, M., Anton, M., Cafferata, E. G. A., Podhajcer, O. L., Plank, C., Mykhaylyk, O. M., & Policastro, L. (2015) · RSC Advances · doi:10.1039/c5ra06562c · Cited by 16
The Preparation of Primary Hematopoietic Cell Cultures From Murine Bone Marrow for Electroporation
Kroeger, K. M., Collins, M., & Ugozzoli, L. A. (2009) · Journal of Visualized Experiments · doi:10.3791/1026 · Cited by 15
Stable transfection of Eimeria necatrix through nucleofection of second generation merozoites
Duan, C., Hu, D., Tang, X., Suo, J., Wang, S., Zhang, S., Tao, G., Li, C., Wang, C., Gu, X., et al. (2019) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2019.01.002 · Cited by 15
Optimization of a transient antibody expression platform towards high titer and efficiency
Greene, E., Cazacu, D., Tamot, N., Castellano, S., Datar, A., Kronkaitis, A., Gebhard, D. H., Reed, J. M., Mawson, P., Florin, L., et al. (2020) · Biotechnology Journal · doi:10.1002/biot.202000251 · Cited by 14
Ma, Y., Sekiya, M., Kainoh, K., Matsuda, T., IWASAKI, H. O., Osaki, Y., Sugano, Y., Suzuki, H., Takeuchi, Y., Miyamoto, T., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.070 · Cited by 13
Using the Gene Pulser MXcell Electroporation System to Transfect Primary Cells with High Efficiency
McCoy, A. M., Collins, M. L., & Ugozzoli, L. A. (2010) · Journal of Visualized Experiments · doi:10.3791/1662 · Cited by 12
Ishiguro, K., Watanabe, O., Nakamura, M., Yamamura, T., Matsushita, M., Goto, H., & Hirooka, Y. (2017) · BioTechniques · doi:10.2144/000114569 · Cited by 8
Keller, A., Scheiding, B., Breitling, R., Licht, A., Hemmerich, P. H., Lorkowski, S., & Reißmann, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27463 · Cited by 8
Voltage Preconditioning Allows Modulated Gene Expression in Neurons Using PEI-complexed siRNA
Sridharan, A., Patel, C., & Muthuswamy, J. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.10 · Cited by 6
Efficiency of two different transfection reagents for use with human NTERA2 cells
Aluigi, M. G., Hofreiter, S., Falugi, C., Pestarino, M., & Candiani, S. (2009) · European Journal of Histochemistry · doi:10.4081/1155 · Cited by 6
Inhibition of PARP1 Increases IRF-dependent Gene Transcription in Jurkat Cells
Wang, C., Du, M., Huang, D. Y., Huang, K., & Huang, K. (2019) · Current Medical Science · doi:10.1007/s11596-019-2043-1 · Cited by 5
Strategies for transfection of bovine mesenchymal stem cells with pBC1-anti-CD3 vector
Duarte, F. B., Brígido, M. M., Melo, E. O., Báo, S. N., & Martins, C. F. (2020) · Animal Biotechnology · doi:10.1080/10495398.2020.1862137 · Cited by 5
The Preparation of Primary Hematopoietic Cell Cultures From Murine Bone Marrow for Electroporation
Kroeger, K. M., Collins, M., & Ugozzoli, L. A. (2009) · Journal of Visualized Experiments · doi:10.3791/1026-v · Cited by 3
A Mammalian Genetic Complementation Assay for Assessing Cellular Resistance to Genotoxic Compounds
Reilly, N. M., & Pittman, D. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9500-4_12 · Cited by 2
Strategies for transfection of bovine mesenchymal stem cells with pBC1-anti-CD3 vector
Duarte, F. B., Báo, S. N., Brígido, M. M., de Araújo, J. M., Melo, E. O., & Martins, C. F. (2019) · Reproduction Fertility and Development · doi:10.1071/rdv32n2ab135 · Cited by 2
Research works printed but not linked: 4
- Karra D, Dahm R. Transfection techniques for neuronal cells. Journal of Neuroscience. 2010 May 5;30(18):6171-7.
- Park JS, Surendran S, Kamendulis LM, Morral N. Comparative nucleic acid transfection e cacy in primary hepatocytes for gene silencing and functional studies. BMC research notes. 2011 Dec;4(1):1- 8.
- Parson II CD. A Generalizable Method to Normalize Luciferase Activity in Transiently Transfected B cells (Doctoral dissertation, North Carolina Agricultural and Technical State University).
- Badakov R, Jaźwińska A. E cient transfection of primary zebra sh broblasts by nucleofection. Cytotechnology. 2006 Jun 1;51(2):105-10.
Cited by
Hosseini-Kharat, M., Bremmell, K. E., Grubor‐Bauk, B., & Prestidge, C. A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.002 · Cited by 39
Jamour, P., Jamali, A., Langeroudi, A. G., Sharafabad, B. E., & Abdoli, A. (2024) · BMC Molecular and Cell Biology · doi:10.1186/s12860-024-00511-x · Cited by 13
Pelle, G. D., Markelc, B., Čerček, U., Živič, U., Coupard, M., Šribar, J., Križaj, I., Arshad, M. S., Božič, T., Gazvoda, L., et al. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214537 · Cited by 4
Metadata
- Authors
- Ewunkem, A. J., & Agee, K.
- Affiliations
- Winston-Salem State University (US)
- ORCID
- Ewunkem, Akamu Jude
- Venue
- Gene & Protein in Disease
- Publisher
- AccScience Publishing
- Published
- 2023-05-29
- Volume
- 2
- Issue
- 2
- Pages
- 0353
- ISSN
- 2811-003X (ISSN-L)
- OpenAlex
- W4382073817
- Semantic Scholar
- b46f2c6154d46cc7d57ec8b759edf74e0ccfcbb0
- Cited by
- 3
- References
- 73
- Citations by year
- 2025: 1 · 2024: 2
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Gene & Protein in Disease (publishedVersion, cc-by)
- Research Square (submittedVersion, cc-by)
- Funders
- National Institute of General Medical Sciences (S06GM076530)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- transfection optimization, transfection reagents, nucleofection, transfection efficiency, cell viability, genotoxicity testing, plasmid DNA delivery, GFP expression, NanoLuc luciferase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.




